Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Gains Marketing Rights To Ajinomoto's Diabetes Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase I compound AJD101 has a new mechanism of action that stimulates insulin independent glucose uptake in preclinical studies, according to the two Tokyo-based drug makers.

You may also be interested in...



Japanese Mergers Provide Opening For Biotech Deals - Novartis Licensing Head

Recent mergers in the Japanese pharmaceutical market have provided U.S. and European biotechs enhanced opportunities to partner with Japanese pharmas looking to fill pipelines and compete globally, according to Novartis Global Head of Business Development and Licensing Anthony Rosenberg. However, Rosenberg cautioned that this same dynamic also could mean fewer opportunities for multinational pharmas to license compounds from their Japanese counterparts

Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head

But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.

Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head

But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel